A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid.

导出 OA

翻译打印收藏纠错

作者： Koné,Kaniga ^[1] ; Daniela M,Cirillo ^[2] ; Sven,Hoffner ^[3] ; Nazir A,Ismail ^[4] ; Devinder,Kaur ^[5] ; Nacer,Lounis ^[6] ; Beverly,Metchock ^[7] ; Gaby E,Pfyffer ^[8] ; Amour,Venter ^[9]

作者单位： Janssen Research & Development, LLC, Titusville, New Jersey, USA kkaniga@its.jnj.com. ^[1] IRCCS, San Raffaele Scientific Institute, Milan, Italy. ^[2] TB Supranational Reference Laboratory, The Public Health Agency of Sweden, Solna, Sweden. ^[3] National TB Reference Laboratory, Center for Tuberculosis, National Institute of Communicable Diseases, Johannesburg, South Africa. ^[4] Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa. ^[5] University of Massachusetts Medical School, Massachusetts Supranational TB Reference Laboratory, Boston, Massachusetts, USA. ^[6] Janssen Pharmaceutica NV, Beerse, Belgium. ^[7] Reference Laboratory, Division of TB Elimination, United States Centers for Disease Control and Prevention, Atlanta, Georgia, USA. ^[8] Department of Medical Microbiology, Center of Laboratory Medicine, Luzerner Kantonsspital LUKS, Luzern, Switzerland. ^[9] TASK Applied Science, SA MRC Centre for TB Research, DST/NRF Center of Excellence for Biomedical TB Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa. ^[10]